Literature DB >> 20397033

The structural parameters for antimicrobial activity, human epithelial cell cytotoxicity and killing mechanism of synthetic monomer and dimer analogues derived from hBD3 C-terminal region.

L Zhou1, S P Liu, L Y Chen, J Li, L B Ong, L Guo, T Wohland, C C Tang, R Lakshminarayanan, J Mavinahalli, C Verma, R W Beuerman.   

Abstract

Understanding the molecular mechanisms of antimicrobial peptide-membrane interactions is crucial in predicting the design of useful synthetic antimicrobial peptide analogues. Defensins are small (3-5 kDa) cysteine-rich cationic proteins which constitute the front line of host innate immunity. In this study, a series of eight 10 AA C-terminal analogues of hBD3 [sequence: RGRKXXRRKK, X = W, F, Y, V, L, I, H, C(Acm); net charge = +7, coded as W2, F2, Y2, V2, L2, I2, H2, and C2] and covalent V2-dimer [(RGRKVVRR)(2)KK] (18 AA, net charge = +11) were synthesized using solid phase peptide synthesis (SPPS) in Fmoc chemistry. Wild-type hBD3 was used as a control in all analyses. W2, V2, and especially Y2 showed high activity selectively against Gram-negative bacteria Pseudomonas aeruginosa in the concentration range of 4.3-9.7 microM. The covalent dimeric form of V2-monomer, V2-dimer, showed increased antibacterial killing compared to the monomeric form, V2-monomer. Cytotoxicity assays on a human conjunctival epithelial cell line (IOBA-NHC cells) showed that no change in viable cell number 24 h after constant exposure to all the eight peptide analogues even at concentrations up to 200 microg/ml. Fluorescence correlation spectroscopy (FCS) was used to study the interaction of these peptides against POPC vesicles (neutral; mammalian cell membrane mimic) and POPG vesicles (negatively charged; bacterial cell membrane mimic). Using FCS, significant aggregation and some leakage of Rhodamine dye were observed with POPG with Y2, W2 and V2 at the concentration of 5-10 mmicroM and no significant aggregation or disruption of vesicles was observed for all peptide analogues tested against POPC. V2-dimer induced more leakage and aggregation than the monomeric form. Overall, V2-dimer is the most effective antimicrobial peptide, with aggregation of POPG vesicles observed at concentrations as low as 1 microM. The concentration of 5-10 microM for Y2 from FCS correlated with the concentration of 5 microM (6.25 microg/ml), at which Y2 showed a cooperative increase in the activity. This suggests a structural transition of Y2 in the 2.5-5 microM concentration range resulting in the correlated increased antimicrobial activity. These results and the FCS together with previous NMR and molecular dynamics (MD) suggested that the charge density-based binding affinity, stable covalent dimerization, the ability to dimerize or even oligomerize and adopt a well-defined structure are important physicochemical properties distinguishing more effective cationic antimicrobial peptides.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20397033     DOI: 10.1007/s00726-010-0565-8

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  9 in total

1.  Progressive structuring of a branched antimicrobial peptide on the path to the inner membrane target.

Authors:  Yang Bai; Shouping Liu; Jianguo Li; Rajamani Lakshminarayanan; Padmanabhan Sarawathi; Charles Tang; Duncun Ho; Chandra Verma; Roger W Beuerman; Konstantin Pervushin
Journal:  J Biol Chem       Date:  2012-06-14       Impact factor: 5.157

2.  Pulmonary surfactant protein A protects lung epithelium from cytotoxicity of human β-defensin 3.

Authors:  Atsushi Saito; Shigeru Ariki; Hitoshi Sohma; Chiaki Nishitani; Kanako Inoue; Nobutaka Ebata; Motoko Takahashi; Yoshihiro Hasegawa; Koji Kuronuma; Hiroki Takahashi; Yoshio Kuroki
Journal:  J Biol Chem       Date:  2012-03-14       Impact factor: 5.157

Review 3.  Role of host-defence peptides in eye diseases.

Authors:  Satya S Kolar; Alison M McDermott
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

4.  Cytotoxicity of HBD3 for dendritic cells, normal human epidermal keratinocytes, hTERT keratinocytes, and primary oral gingival epithelial keratinocytes in cell culture conditions.

Authors:  Nattawut Leelakanok; Carol L Fischer; Amber M Bates; Janet M Guthmiller; Georgia K Johnson; Aliasger K Salem; Kim A Brogden; Nicole K Brogden
Journal:  Toxicol Lett       Date:  2015-09-11       Impact factor: 4.372

5.  Development of second generation peptides modulating cellular adiponectin receptor responses.

Authors:  Laszlo Otvos; Daniel Knappe; Ralf Hoffmann; Ilona Kovalszky; Julia Olah; Tim D Hewitson; Roma Stawikowska; Maciej Stawikowski; Predrag Cudic; Feng Lin; John D Wade; Eva Surmacz; Sandor Lovas
Journal:  Front Chem       Date:  2014-10-17       Impact factor: 5.221

Review 6.  Host Defense Peptides at the Ocular Surface: Roles in Health and Major Diseases, and Therapeutic Potentials.

Authors:  Darren Shu Jeng Ting; Imran Mohammed; Rajamani Lakshminarayanan; Roger W Beuerman; Harminder S Dua
Journal:  Front Med (Lausanne)       Date:  2022-06-16

7.  Synthetic multivalent antifungal peptides effective against fungi.

Authors:  Rajamani Lakshminarayanan; Shouping Liu; Jianguo Li; Muruganantham Nandhakumar; Thet Tun Aung; Eunice Goh; Jamie Ya Ting Chang; Padhmanaban Saraswathi; Charles Tang; Siti Radiah Binte Safie; Lim Yih Lin; Howard Riezman; Zhou Lei; Chandra S Verma; Roger W Beuerman
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

8.  Engineering and characterization of human β-defensin-3 and its analogues and microcin J25 peptides against Mannheimia haemolytica and bovine neutrophils.

Authors:  Harpreet Dhingra; Kamaljit Kaur; Baljit Singh
Journal:  Vet Res       Date:  2021-06-10       Impact factor: 3.683

Review 9.  Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrug-resistant Gram-negatives.

Authors:  María Escobar-Salom; Gabriel Torrens; Elena Jordana-Lluch; Antonio Oliver; Carlos Juan
Journal:  Biol Rev Camb Philos Soc       Date:  2022-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.